Adoptive Immunity Mediated by HLA-A*0201 Restricted Asp F16 Peptides-specific CD8+ T Cells Against Aspergillus Fumigatus Infection

Overview

Journal Eur J Clin Microbiol Infect Dis

Publisher Springer

Specialties Infectious Diseases
Microbiology

Date 2012 Jun 15

PMID 22696051

Citations 10

Authors

Z Sun

P Zhu

L Li

Z Wan

Z Zhao

R Li

Affiliations

Soon will be listed here.

Abstract

Aspergillus fumigatus (A. fumigatus) is the most common pathogen of invasive aspergillosis (IA), a life-threatening infection in immunocompromised patients. Recent findings revealed that CD8+ T cells can mediate cytotoxic activity against A. fumigatus. Here, we bioinformatically identified three HLA-A*0201-restricted peptides from Asp f16, an A. fumigatus antigen which was previously shown to be involved in T cell immunity. Our immunological results demonstrated that these peptides can potently induce cytotoxic T lymphocyte (CTL) response in CD8+ T cells, thus, damaging the conidia and hyphae of A. fumigatus. Moreover, the Asp f16 peptides can also raise Th1 cell-like response, as measured by interferon-γ (IFN-γ) enzyme-linked immunosorbent spot (ELISPOT). Furthermore, we established an invasive pulmonary aspergillosis model in HLA-A*0201 transgenic mice. Adoptive transfer of Asp f16 peptides-specific CTL significantly extended the overall survival time in the A. fumigatus-infected immunocompromised mice. In conclusion, our results demonstrate that the Asp f16 peptides might provide immunity against invasive A. fumigatus infection.

Citing Articles

Host Transcriptional Regulatory Genes and Microbiome Networks Crosstalk through Immune Receptors Establishing Normal and Tumor Multiomics Metafirm of the Oral-Gut-Lung Axis.

Otalora-Otalora B, Lopez-Rivera J, Aristizabal-Guzman C, Isaza-Ruget M, Alvarez-Moreno C Int J Mol Sci. 2023; 24(23).

PMID: 38068961 PMC: 10706695. DOI: 10.3390/ijms242316638.

Fungal Vaccine Development: State of the Art and Perspectives Using Immunoinformatics.

Inacio M, Moreira A, Cruz-Leite V, Mattos K, Souza Silva L, Venturini J J Fungi (Basel). 2023; 9(6).

PMID: 37367569 PMC: 10301004. DOI: 10.3390/jof9060633.

Reinforcing the Immunocompromised Host Defense against Fungi: Progress beyond the Current State of the Art.

Karavalakis G, Yannaki E, Papadopoulou A J Fungi (Basel). 2021; 7(6).

PMID: 34204025 PMC: 8228486. DOI: 10.3390/jof7060451.

Immunomodulation as a Therapy for Infection: Current Status and Future Perspectives.

Lauruschkat C, Einsele H, Loeffler J J Fungi (Basel). 2018; 4(4).

PMID: 30558125 PMC: 6308942. DOI: 10.3390/jof4040137.

Immunomodulation as Therapy for Fungal Infection: Are We Closer?.

Sam Q, Yew W, Seneviratne C, Chang M, Chai L Front Microbiol. 2018; 9:1612.

PMID: 30090091 PMC: 6068232. DOI: 10.3389/fmicb.2018.01612.

References

Bar E, Gladiator A, Bastidas S, Roschitzki B, Acha-Orbea H, Oxenius A . A novel Th cell epitope of Candida albicans mediates protection from fungal infection. J Immunol. 2012; 188(11):5636-43. DOI: 10.4049/jimmunol.1200594. View

Iversen M, Burton C, Vand S, Skovfoged L, Carlsen J, Milman N . Aspergillus infection in lung transplant patients: incidence and prognosis. Eur J Clin Microbiol Infect Dis. 2007; 26(12):879-86. DOI: 10.1007/s10096-007-0376-3. View

Zhang L, Wang M, Li R, Calderone R . Expression of Aspergillus fumigatus virulence-related genes detected in vitro and in vivo with competitive RT-PCR. Mycopathologia. 2005; 160(3):201-6. DOI: 10.1007/s11046-005-0141-z. View

Sangha R, Butts C . L-BLP25: a peptide vaccine strategy in non small cell lung cancer. Clin Cancer Res. 2007; 13(15 Pt 2):s4652-4. DOI: 10.1158/1078-0432.CCR-07-0213. View

Cenci E, Mencacci A, Bacci A, Bistoni F, Kurup V, Romani L . T cell vaccination in mice with invasive pulmonary aspergillosis. J Immunol. 2000; 165(1):381-8. DOI: 10.4049/jimmunol.165.1.381. View

Alvarez C, Wiederhold N, McConville J, Peters J, Najvar L, Graybill J . Aerosolized nanostructured itraconazole as prophylaxis against invasive pulmonary aspergillosis. J Infect. 2007; 55(1):68-74. DOI: 10.1016/j.jinf.2007.01.014. View

Wang W, Zhao C, Zhou J, Wang Y, Shen C, Zhou D . Invasive pulmonary aspergillosis in patients with HBV-related liver failure. Eur J Clin Microbiol Infect Dis. 2011; 30(5):661-7. DOI: 10.1007/s10096-010-1137-2. View

Melief C, van der Burg S . Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer. 2008; 8(5):351-60. DOI: 10.1038/nrc2373. View

Asif A, Oellerich M, Amstrong V, Riemenschneider B, Monod M, Reichard U . Proteome of conidial surface associated proteins of Aspergillus fumigatus reflecting potential vaccine candidates and allergens. J Proteome Res. 2006; 5(4):954-62. DOI: 10.1021/pr0504586. View

10.

Chaudhary N, Staab J, Marr K . Healthy human T-Cell Responses to Aspergillus fumigatus antigens. PLoS One. 2010; 5(2):e9036. PMC: 2822840. DOI: 10.1371/journal.pone.0009036. View

11.

Aichele P, Hengartner H, Zinkernagel R, Schulz M . Antiviral cytotoxic T cell response induced by in vivo priming with a free synthetic peptide. J Exp Med. 1990; 171(5):1815-20. PMC: 2187909. DOI: 10.1084/jem.171.5.1815. View

12.

Stanzani M, Orciuolo E, Lewis R, Kontoyiannis D, Martins S, St John L . Aspergillus fumigatus suppresses the human cellular immune response via gliotoxin-mediated apoptosis of monocytes. Blood. 2004; 105(6):2258-65. DOI: 10.1182/blood-2004-09-3421. View

13.

Ramadan G, Davies B, Kurup V, Keever-Taylor C . Generation of Th1 T cell responses directed to a HLA Class II restricted epitope from the Aspergillus f16 allergen. Clin Exp Immunol. 2005; 139(2):257-67. PMC: 1809287. DOI: 10.1111/j.1365-2249.2005.02699.x. View

14.

Stephens-Romero S, Mednick A, Feldmesser M . The pathogenesis of fatal outcome in murine pulmonary aspergillosis depends on the neutrophil depletion strategy. Infect Immun. 2004; 73(1):114-25. PMC: 538996. DOI: 10.1128/IAI.73.1.114-125.2005. View

15.

Bozza S, Gaziano R, Lipford G, Montagnoli C, Bacci A, Di Francesco P . Vaccination of mice against invasive aspergillosis with recombinant Aspergillus proteins and CpG oligodeoxynucleotides as adjuvants. Microbes Infect. 2002; 4(13):1281-90. DOI: 10.1016/s1286-4579(02)00007-2. View

16.

Latge J . Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev. 1999; 12(2):310-50. PMC: 88920. DOI: 10.1128/CMR.12.2.310. View

17.

Ramadan G, Davies B, Kurup V, Keever-Taylor C . Generation of cytotoxic T cell responses directed to human leucocyte antigen Class I restricted epitopes from the Aspergillus f16 allergen. Clin Exp Immunol. 2005; 140(1):81-91. PMC: 1809331. DOI: 10.1111/j.1365-2249.2005.02738.x. View

18.

Stevens D . Vaccinate against aspergillosis! A call to arms of the immune system. Clin Infect Dis. 2004; 38(8):1131-6. DOI: 10.1086/382882. View

19.

Wuthrich M, Filutowicz H, Warner T, Deepe Jr G, Klein B . Vaccine immunity to pathogenic fungi overcomes the requirement for CD4 help in exogenous antigen presentation to CD8+ T cells: implications for vaccine development in immune-deficient hosts. J Exp Med. 2003; 197(11):1405-16. PMC: 2193905. DOI: 10.1084/jem.20030109. View

20.

Ma L, Spurrell J, Wang J, Neely G, Epelman S, Krensky A . CD8 T cell-mediated killing of Cryptococcus neoformans requires granulysin and is dependent on CD4 T cells and IL-15. J Immunol. 2002; 169(10):5787-95. DOI: 10.4049/jimmunol.169.10.5787. View